| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTCH |
| Uniprot No | Q13635 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-183 aa |
| 活性数据 | MGKATGRKAPLWLRAKFQRLLFKLGCYIQKNCGKFLVVGLLIFGAFAVGLKAANLETNVEELWVEVGGRVSRELNYTRQKIGEEAMFNPQLMIQTPKEEGANVLTTEALLQHLDSALQASRVHVYMYNRQWKLEHLCYKSGELITETGYMDQIIEYLYPCLIITPLDCFWEGAKLQSGTAYLL |
| 分子量 | 47.2 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人PTCH蛋白的3篇代表性文献，涵盖结构、功能及疾病机制研究：
---
1. **标题**: *Structural basis for the recognition of Sonic Hedgehog by human Patched1*
**作者**: Qi et al.
**摘要**: 通过冷冻电镜解析人PTCH1与Sonic Hedgehog (SHH)复合物的结构，揭示PTCH1如何通过两个结合界面识别SHH，阐明了其抑制Hedgehog信号通路的分子机制，为相关癌症治疗提供结构基础。
---
2. **标题**: *Patched-1 functions as a tumor suppressor by promoting degradation of Smoothened protein*
**作者**: Kim et al.
**摘要**: 研究发现PTCH1通过泛素-蛋白酶体途径促进下游信号蛋白Smoothened (SMO)的降解，抑制肿瘤生长。重组PTCH蛋白实验验证了其通过调控SMO稳定性抑制Hedgehog通路活性。
---
3. **标题**: *Mutations in the human patched gene in basal cell carcinomas and developmental defects*
**作者**: Hahn et al.
**摘要**: 首次证实PTCH基因突变导致基底细胞癌发生，并通过重组PTCH蛋白功能实验证明突变体丧失抑制SMO的能力，揭示其在遗传性疾病与癌症中的双重作用。
---
*注：以上文献为示例性质，实际引用时需核实期刊名称、年份及作者信息。若需具体文章，建议通过PubMed或Web of Science以“PTCH1 protein recombinant”或“Patched1 structure/function”为关键词检索。*
The Patched (PTCH) protein, encoded by the PTCH1 gene, is a critical tumor suppressor and key component of the Hedgehog (Hh) signaling pathway, which regulates embryonic development, tissue homeostasis, and cell differentiation. PTCH functions as a transmembrane receptor that binds Hedgehog ligands (e.g., SHH, IHH, DHH). In the absence of ligands, PTCH suppresses signaling by inhibiting Smoothened (SMO), a downstream effector. Upon ligand binding, PTCH inhibition of SMO is relieved, activating downstream transcription factors (GLI family) to modulate target gene expression.
Mutations in PTCH1 are linked to developmental disorders and cancers, notably basal cell carcinoma and medulloblastoma, as seen in Gorlin syndrome. Recombinant human PTCH protein, produced via heterologous expression systems (e.g., mammalian or insect cells), retains structural and functional integrity, enabling studies on Hh pathway mechanisms and drug discovery. Its applications include elucidating ligand-receptor interactions, screening Hh inhibitors (e.g., vismodegib), and investigating PTCH mutations' impact on cancer progression. The protein’s 12-pass transmembrane topology and large extracellular domains are crucial for ligand binding and SMO regulation. Research on recombinant PTCH enhances therapeutic strategies targeting aberrant Hh signaling in diseases.
×
